All News

Indu Subramanian, MD: Social Prescribing for Patients With Parkinson Disease

September 18, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers explained how social prescribing can play a key role in the prevention of social isolation.

Ozanimod Shows Long-Term Safety, Efficacy in Open-Label Extension

September 18, 2020

Along with being generally well tolerated, ozanimod was able to help most patients become relapse free without disability progression.

The Changing Treatment Landscape for Acute Migraine

September 18, 2020

David Dodick, MD, reviews changes to the treatment landscape for acute migraine.

Sumifilam Improves Multiple Alzheimer Disease Biomarkers in Phase 2b Study

September 17, 2020

The results point to the potential for sumifilam to become a transformative treatment for patients with Alzheimer disease.

Stewart Factor, MD: Long-Term Data on Apomorphine Sublingual Film in Parkinson

September 17, 2020

The director of the Movement Disorders Program and Vance Lanier Chair of Neurology at Emory University School of Medicine gave his perspective on the interim findings of a long-term safety study of apomorphine sublingual film.

Addressing Loneliness and Social Isolation in Patients With Parkinson Disease

September 17, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers offered background the inspiration for the study and why loneliness should be addressed in these patients.

Satralizumab Reduces Risk of Relapse, Including in Treatment-Naïve NMOSD

September 17, 2020

Two posters presented at MDS 2020 confirm satralizumab’s ability to reduce protocol-defined relapse including in patients with treatment-naïve NMOSD.

Joaquim Ferreria, MD, PhD: Opicapone’s Use in Levodopa-Treated Patients With Parkinson Disease

September 16, 2020

The head of the Laboratory of Clinical Pharmacology and Therapeutics at the University of Lisbon gave his perspective on the importance of the study population of this analysis.

Apomorphine Sublingual Film Shows Long-Term Efficacy in OFF Episode Treatment

September 16, 2020

The recently approved apomorphine sublingual film (Kynmobi; Sunovion) maintained efficacy over the long-term, with at least 74% of patients experiencing full ON within 30 minutes post-dose at each time point.

THN102 Is Safe, Improves Excessive Daytime Sleepiness in Parkinson Disease

September 16, 2020

The investigational drug consistently increased the proportion of patients no longer suffering from daytime sleepiness during treatment.